FR2686896B1 - Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique. - Google Patents

Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.

Info

Publication number
FR2686896B1
FR2686896B1 FR9201128A FR9201128A FR2686896B1 FR 2686896 B1 FR2686896 B1 FR 2686896B1 FR 9201128 A FR9201128 A FR 9201128A FR 9201128 A FR9201128 A FR 9201128A FR 2686896 B1 FR2686896 B1 FR 2686896B1
Authority
FR
France
Prior art keywords
listeria monocytogenes
vaccine
attenue
mutant
recombinant strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9201128A
Other languages
English (en)
Other versions
FR2686896A1 (fr
Inventor
Pascale Cossart
Christine Kocks
Pierre Goossens
Genevieve Milon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur de Lille
Original Assignee
Institut Pasteur de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur de Lille filed Critical Institut Pasteur de Lille
Priority to FR9201128A priority Critical patent/FR2686896B1/fr
Priority to PCT/FR1993/000105 priority patent/WO1993015212A1/fr
Publication of FR2686896A1 publication Critical patent/FR2686896A1/fr
Application granted granted Critical
Publication of FR2686896B1 publication Critical patent/FR2686896B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
FR9201128A 1992-01-31 1992-01-31 Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique. Expired - Fee Related FR2686896B1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FR9201128A FR2686896B1 (fr) 1992-01-31 1992-01-31 Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
PCT/FR1993/000105 WO1993015212A1 (fr) 1992-01-31 1993-02-01 Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigene vaccinal et utilisation comme vaccin ou composition diagnostique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9201128A FR2686896B1 (fr) 1992-01-31 1992-01-31 Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.

Publications (2)

Publication Number Publication Date
FR2686896A1 FR2686896A1 (fr) 1993-08-06
FR2686896B1 true FR2686896B1 (fr) 1995-01-06

Family

ID=9426237

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9201128A Expired - Fee Related FR2686896B1 (fr) 1992-01-31 1992-01-31 Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.

Country Status (2)

Country Link
FR (1) FR2686896B1 (fr)
WO (1) WO1993015212A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
CN1758923B (zh) * 2003-02-06 2013-04-24 阿杜罗生物科技公司 进入非吞噬细胞被衰减的利斯特氏菌、含有该利斯特氏菌的疫苗

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) * 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US8791237B2 (en) 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7662396B2 (en) 2001-03-26 2010-02-16 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US7794729B2 (en) 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US6051237A (en) * 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7820180B2 (en) 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
DE19754938B4 (de) * 1997-12-11 2006-04-20 Christoph von Dr. Eichel-Streiber TGC-Verfahren zur Induktion einer zielgerichteten, somatischen Transgenität
DE19949594A1 (de) * 1999-10-14 2001-04-26 Deutsches Krebsforsch Rekombinante attenuierte Listerien zur Immuntherapie
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP1303299B1 (fr) 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Utilisation des peptides prokaryotic pest-like pour augmenter l'immunogénicité des antigènes
WO2001077335A2 (fr) * 2000-04-11 2001-10-18 Institut Pasteur Genome de listeria monocytogenes, polypeptides et utilisations
US7700344B2 (en) 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
JP4839209B2 (ja) 2003-02-06 2011-12-21 アンザ セラピューティクス，インコーポレイテッド 改変された自由生活微生物、ワクチン組成物、およびそれらの使用方法
PT1592441E (pt) * 2003-02-06 2012-05-21 Aduro Biotech Listeria atenuada relativamente à entrada em células não patogénicas, vacinas compreendendo a listeria e métodos para sua utilização
TW200530399A (en) * 2003-12-24 2005-09-16 Cerus Corp Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7842289B2 (en) 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
EP1708741B1 (fr) * 2003-12-24 2016-03-30 Aduro Biotech Molecules d'acides nucleiques codant pour des proteines de fusion comprenant des antigenes et des polypeptides de signal bacteriens, cassettes d'expression, et bacteries, et leur methodes d'utilisation
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
DK2977456T3 (en) 2006-08-15 2018-01-22 Univ Pennsylvania Compositions comprising HMW-MAA and fragments thereof for the treatment of cancer
US8268326B2 (en) 2006-08-15 2012-09-18 The Trustees Of The University Of Pennsylvania Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof
WO2009024426A1 (fr) * 2007-07-27 2009-02-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions d'immunisation pour induire la mort de voisinage de pathogènes
EP2288379A4 (fr) 2008-05-19 2012-08-08 Advaxis Système de double distribution pour des antigènes hétérologues
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
DK2403935T3 (en) 2009-03-04 2017-09-11 Univ Pennsylvania COMPOSITIONS CONTAINING ANGIOGENIC FACTORS AND METHODS OF USE THEREOF
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
CN107412756A (zh) 2010-10-01 2017-12-01 宾夕法尼亚大学理事会 李斯特菌疫苗载体用于在寄生虫感染的个体中扭转免疫无应答的用途
EP3332804A1 (fr) 2011-03-11 2018-06-13 Advaxis, Inc. Adjuvants à base de listeria
EP2825195A4 (fr) 2012-03-12 2015-10-07 Advaxis Inc Inhibition de la fonction des cellules suppresseurs après traitement par un vaccin à base de listeria
CN109735477B (zh) * 2018-12-03 2022-07-05 扬州大学 单核细胞增生李斯特菌三基因缺失减毒突变株制备及其应用
CN117701565B (zh) * 2023-12-01 2024-09-03 中国农业大学 一种单核细胞增生李斯特氏菌强组成型启动子及其应用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
US7927606B2 (en) 2003-02-06 2011-04-19 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
CN1758923B (zh) * 2003-02-06 2013-04-24 阿杜罗生物科技公司 进入非吞噬细胞被衰减的利斯特氏菌、含有该利斯特氏菌的疫苗

Also Published As

Publication number Publication date
WO1993015212A1 (fr) 1993-08-05
FR2686896A1 (fr) 1993-08-06

Similar Documents

Publication Publication Date Title
FR2686896B1 (fr) Mutant attenue de listeria monocytogenes; souche recombinante de listeria monocytogenes, utilisation comme vecteurs heterologues d'antigenes vaccinal et utilisation comme vaccin ou composition diagnostique.
HK1048496A1 (zh) 應力蛋白及其使用
EP0835133A4 (fr) Compositions recombinantes et compositions combinees de virus de la rage et de la variole, et leurs utilisations
IL134392A0 (en) Vaccine against hpv
CA2132836A1 (fr) Immunisation par injection d'une unite de transcription genetique
BR9605153B1 (pt) vacina de combinação, e, kit de vacinação.
HU9400741D0 (en) Immunoreactive hepatitis c virus polypeptide compositions
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
DE69518910D1 (de) Verfahren zur herstellung von viralen vektoren von mindestens 20kb durch intermolekulare homologe rekombination in einer prokaryotischen zelle
NL300106I2 (nl) N-terminaal chemisch gemodificeerde eiwitpreparaten en werkwijzen.
EP0330359A3 (fr) Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
EP0342860A3 (fr) Nouvelle protéine, séquences contenant le gène de cette protéine, vecteurs, procédés de préparation et utilisation
NZ309659A (en) Composition comprising LbeIF4A and/or LmeIF4A polypeptides (Leishmania antigen) and methods for enhancing immune responses
AUPM885194A0 (en) Synthetic peptides and vaccines comprising same
CA2169297A1 (fr) Vaccins a base de cochleate proteique ou peptidique et procedes d'immunisation faisant appel a ces vaccins
CA2042236A1 (fr) Epitopes ayant un effet seroreactif sur les proteines du papillomavirus humain (hpv) 18
AU6705594A (en) Compositions of antigen containing recombinant salmonella, their use in anti-malarial vaccines and method for their preparation
CA2132742A1 (fr) Peptides synthetiques et vaccins contre les parvovirus
WO1995012682A3 (fr) Vecteur viral a antigenes du virus de la maladie des muqueuses (bvdv)
CA2141871A1 (fr) Nouvelles souches attenuees de pseudomonas aeruginosa
CA2097702A1 (fr) Vaccin contre les dermatophyties
CA2286399A1 (fr) Proteines de recombinaison d'une souche pakistanaise de l'hepatite e et leurs utilisation dans des methodes diagnostiques et des vaccins
CA2176929A1 (fr) Vaccin contre les oreillons contenant une souche virale jeryl-lynn
KR950701821A (ko) 피임 백신(contraceptive vaccine)
WO1992014818A3 (fr) Systeme d'expression d'entomopoxvirus comprenant des sequences de spheroïdine ou de thymidine-kinase

Legal Events

Date Code Title Description
ST Notification of lapse